---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-015352"
form_type: "8-K"
ticker: "APYX"
cik: "0000719135"
company_name: "Apyx Medical Corp"
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T22:16:56.982571+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Apyx Medical Q1 revenue $12.5M (+32% YoY); raises FY2026 guidance

## Summary
- Total revenue $12.5M, up 32% YoY; Surgical Aesthetics grew 36% to $10.7M.
- Net loss narrowed to $2.1M ($0.05 loss per share) from $4.2M ($0.10 loss).
- Adjusted EBITDA loss improved to $0.3M from $2.4M in prior year.
- Raised FY2026 revenue guidance to $59M-$60M from prior $57.5M-$58.5M.
- International sales strong, especially South Korea; Renuvion won NewBeauty award.

## SEC filing metadata
- accession: 0001437749-26-015352
- form_type: 8-K
- ticker: APYX
- cik: 0000719135
- company_name: Apyx Medical Corp
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/719135/000143774926015352/0001437749-26-015352-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/719135/000143774926015352/apyx20260107_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-015352
- JSON: https://secwatch.observer/filing/0001437749-26-015352.json
- Plain text: https://secwatch.observer/filing/0001437749-26-015352.txt

## Source-grounded claims
- claim_id: 802b8290608212feec39b5af2068d70387732886
  claim: Apyx Medical Corp reported the first quarter ended March 31, 2026 results: revenue total revenue of $12.5 million, net income Net loss attributable to stockholders of $2.1 million, EPS $0.05 per share. Guidance raised.
  evidence_excerpt: 99.1) --- EX-99.1 2 ex_905122.htm EXHIBIT 99.1 ex_905122.htm EXHIBIT 99.1 Apyx Medical Corporation Reports First Quarter 2026 Financial Results • Reported total revenue of $12.5 million in the first quarter of 2026 primarily driven by 36% growth in the Surgical Aesthetics segment • Raised total revenue guidance for FY2026 to a range of $59.0 million to $60.0
  evidence_url: https://www.sec.gov/Archives/edgar/data/719135/000143774926015352/0001437749-26-015352-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.